Role of Autoreactivity in Pathogenesis of Chronic GVHD

自身反应性在慢性 GVHD 发病机制中的作用

基本信息

  • 批准号:
    7392801
  • 负责人:
  • 金额:
    $ 35.37万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-07-01 至 2010-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Chronic graft-vs.-host disease (GVHD) is the major morbidity and mortality of long-term survivors of allogeneic hematopoietic cell transplantation (HCT), and therapies that prevent acute GVHD are unsuccessful in preventing chronic GVHD. Chronic GVHD is considered an autoimmune collagen-vascular disease with clinical features similar to autoimmune scleroderma and systemic lupus erythematosus (SLE). However, the pathogenesis of chronic GVHD is poorly understood. It is unclear how autoreactive T cells are generated in chronic GVHD recipients; it is largely unknown how B cells and autoantibodies contribute to the pathogenesis, although it was recently reported that anti-CD20 mAb ameliorated refractory chronic GVHD by depleting B cells. We recently developed a new model of chronic GVHD, in which DBA/2 donor (H-2d) spleen cells were injected into sub-lethally irradiated MHC matched but minor antigen mismatched BALB/c (H-2d) recipients, and the recipients developed autoimmune-like GVHD with high levels of serum autoantibodies, sclerodermatous skin damage, and glomerulonephritis. Disease induction required both donor CD4+ T and B220+ B cells in transplants. In contrast, addition of donor CD25+CD4+ regulatory T (Treg) cells to transplants prevented the disease development. Therefore, we hypothesize that activation and expansion of the quiescent donor autoreactive CD4+ T and B cells from transplants in allogeneic recipients lead to the development of chronic GVHD. Furthermore, the activated autoreactive B cells play a central role in the activation of autoreactive CD4+ T cells and amplification of the autoimmune response. In contrast, Treg cells suppress the autoimmune response in chronic GVHD. To test our hypothesis, we will 1) determine the origin of autoreactive CD4+ T cells by comparing disease induction in euthymic and athymic recipients; and identify the donor CD4+T cell subsets in transplants responsible for the disease induction; 2) determine the role of donor autoreactive B cells in transplants in the activation of autoreactive CD4+ T cells and the disease induction; 3) determine whether natural as well as Foxp3 transduced CD25+CD4+Treg cells can be used to prevent and treat autoimmune-like chronic GVHD. These studies will provide new insights into the pathogenesis of chronic GVHD, and provide new approaches for preventing and treating chronic GVHD.
描述(由申请人提供):慢性移植物vs.-宿主疾病(GVHD)是同种异体造血细胞移植(HCT)长期存活者的主要发病率和死亡率,并且预防急性GVHD的疗法在预防慢性GVHD方面是不成功的。慢性GVHD被认为是一种自身免疫性胶原血管疾病,其临床特征类似于自身免疫性硬皮病和系统性红斑狼疮(SLE)。然而,慢性GVHD的发病机制知之甚少。目前尚不清楚慢性GVHD受者中自身反应性T细胞是如何产生的; B细胞和自身抗体如何参与发病机制在很大程度上是未知的,尽管最近报道抗CD 20 mAb通过耗尽B细胞来改善难治性慢性GVHD。我们最近开发了一种新的慢性GVHD模型,其中DBA/2供体(H-2d)脾细胞被注射到亚致死剂量照射的MHC匹配但次要抗原不匹配的BALB/c(H-2d)受体中,并且受体发展为具有高水平血清自身抗体、硬皮病皮肤损伤和肾小球肾炎的自身免疫样GVHD。在移植中,疾病诱导需要供体CD 4 + T和B220+ B细胞。相反,加入供体CD 25 + CD 4+调节性T细胞, (Treg)细胞移植阻止了疾病的发展。因此,我们推测,同种异体受者移植物中静止供体自身反应性CD 4 + T和B细胞的激活和扩增导致慢性GVHD的发展。此外,活化的自身反应性B细胞在自身反应性CD 4 + T细胞的活化和自身免疫应答的扩增中起核心作用。相比之下,Treg细胞抑制慢性GVHD中的自身免疫反应。为了验证我们的假设,我们将1)通过比较正常胸腺和无胸腺受者的疾病诱导来确定自身反应性CD 4 + T细胞的来源;并鉴定移植物中负责疾病诱导的供体CD 4 +T细胞亚群; 2)确定移植物中供体自身反应性B细胞在自身反应性CD 4 + T细胞活化和疾病诱导中的作用; 3)确定天然以及Foxp 3转导的CD 25 + CD 4 +Treg细胞是否可用于预防和治疗自身免疫样慢性GVHD。这些研究将为慢性GVHD的发病机制提供新的认识,并为慢性GVHD的预防和治疗提供新的途径。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Defu Zeng其他文献

Defu Zeng的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Defu Zeng', 18)}}的其他基金

Pathogenesis, prevention and treatment of corticosteroid-resistant gut GVHD
皮质类固醇耐药性肠道GVHD的发病机制及防治
  • 批准号:
    10585851
  • 财政年份:
    2023
  • 资助金额:
    $ 35.37万
  • 项目类别:
PD-L1 interacts with CD80 and PD-1 to regulate GVHD and GVL activity
PD-L1 与 CD80 和 PD-1 相互作用调节 GVHD 和 GVL 活性
  • 批准号:
    10335189
  • 财政年份:
    2018
  • 资助金额:
    $ 35.37万
  • 项目类别:
Role of Autoreactivity in Pathogenesis of Chronic GVHD
自身反应性在慢性 GVHD 发病机制中的作用
  • 批准号:
    8099399
  • 财政年份:
    2010
  • 资助金额:
    $ 35.37万
  • 项目类别:
Role of Autoreactivity in Pathogenesis of Chronic GVHD
自身反应性在慢性 GVHD 发病机制中的作用
  • 批准号:
    7204111
  • 财政年份:
    2005
  • 资助金额:
    $ 35.37万
  • 项目类别:
Role of Autoreactivity in Pathogenesis of Chronic GVHD
自身反应性在慢性 GVHD 发病机制中的作用
  • 批准号:
    8628732
  • 财政年份:
    2005
  • 资助金额:
    $ 35.37万
  • 项目类别:
Role of Autoreactivity in Pathogenesis of Chronic GVHD
自身反应性在慢性 GVHD 发病机制中的作用
  • 批准号:
    8440847
  • 财政年份:
    2005
  • 资助金额:
    $ 35.37万
  • 项目类别:
Role of Autoreactivity in Pathogenesis of Chronic GVHD
自身反应性在慢性 GVHD 发病机制中的作用
  • 批准号:
    7591064
  • 财政年份:
    2005
  • 资助金额:
    $ 35.37万
  • 项目类别:
Role of Autoreactivity in Pathogenesis of Chronic GVHD
自身反应性在慢性 GVHD 发病机制中的作用
  • 批准号:
    8021854
  • 财政年份:
    2005
  • 资助金额:
    $ 35.37万
  • 项目类别:
Role of autoreactivity in the pathogenesis of chronic GVHD
自身反应性在慢性 GVHD 发病机制中的作用
  • 批准号:
    9055483
  • 财政年份:
    2005
  • 资助金额:
    $ 35.37万
  • 项目类别:
Role of autoreactivity in the pathogenesis of chronic GVHD
自身反应性在慢性 GVHD 发病机制中的作用
  • 批准号:
    9189582
  • 财政年份:
    2005
  • 资助金额:
    $ 35.37万
  • 项目类别:

相似海外基金

HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
  • 批准号:
    10039902
  • 财政年份:
    2022
  • 资助金额:
    $ 35.37万
  • 项目类别:
    EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
  • 批准号:
    21K15925
  • 财政年份:
    2021
  • 资助金额:
    $ 35.37万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
  • 批准号:
    21K08410
  • 财政年份:
    2021
  • 资助金额:
    $ 35.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
  • 批准号:
    20K21672
  • 财政年份:
    2020
  • 资助金额:
    $ 35.37万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
  • 批准号:
    18K16395
  • 财政年份:
    2018
  • 资助金额:
    $ 35.37万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
  • 批准号:
    17K10951
  • 财政年份:
    2017
  • 资助金额:
    $ 35.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
  • 批准号:
    370541
  • 财政年份:
    2017
  • 资助金额:
    $ 35.37万
  • 项目类别:
    Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
  • 批准号:
    16K10863
  • 财政年份:
    2016
  • 资助金额:
    $ 35.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
  • 批准号:
    276706135
  • 财政年份:
    2015
  • 资助金额:
    $ 35.37万
  • 项目类别:
    Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
  • 批准号:
    15H04915
  • 财政年份:
    2015
  • 资助金额:
    $ 35.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了